REMEGEN's stock plummeted 6.51% during intraday trading on Monday, reflecting significant selling pressure.

The sharp decline follows the company's recently disclosed first-quarter results, which showed a steep sequential drop in net profit. Despite year-over-year revenue growth, net profit attributable to shareholders fell approximately 73% quarter-over-quarter. This sharp earnings contraction, coupled with a prior period of stock price gains, has triggered profit-taking activity. Additionally, sustained net selling by southbound capital over recent weeks has contributed to capital outflow pressures.

The broader biotechnology sector also exhibited weakness during the session, with several major peers trading lower, which further weighed on investor sentiment towards REMEGEN.